Novadaq Technologies Inc.TSX: NDQ

Novadaq to Present at Scientific and Investor Conferences

· Issued by Novadaq Technologies Inc. via CNW
Showcasing at AATS and Presenting at ARVO and BioFinance

TORONTO, April 25 /CNW/ - Novadaq(R) Technologies Inc. (TSX: NDQ), a
developer of medical imaging systems for the operating room, announced today
that it will be showcasing the SPY(R) System at the 86th Annual Meeting of the
American Association for Thoracic Surgery (AATS), presenting the OPTTX(R)
System at the 2006 Association for Research in Vision and Ophthalmology (ARVO)
Conference and presenting corporate highlights at BioFinance 2006.
Novadaq will showcase the SPY System at the Sorin Group booth exhibit at
AATS, taking place at the Pennsylvania Convention Center. On Monday, May 1 at
12:30 p.m., guest speaker Dr. Christine McCarty, cardiac surgeon at Harrisburg
Hospital in Pennsylvania, will engage visiting guests in a discussion focusing
on her clinical experience with the SPY System.
Dr. Giovanni Staurenghi, Associate Professor of Ophthalmology, Department
of Clinical Science Luigi Sacco, University of Milan, Italy, will present a
poster at ARVO on clinical research completed using Novadaq's OPTTX System for
the diagnosis and treatment of wet Age-related Macular Degeneration (AMD). The
poster, entitled Dye-enhanced Photocoagulation (DEP) for Treatment of
Choroidal Neovascularization in Age-related Macular Degeneration, will take
place in Hall B/C of the Greater Fort Lauderdale/Broward County Convention
Center at 3:00 p.m. on May 1, 2006.
Arun Menawat, President and CEO of Novadaq, will present a corporate
overview and update of the company and its development programs at BioFinance.
The presentation, highlighting the commercialization of the SPY(R) System for
real-time imaging during bypass graft surgery, as well as a growing pipeline
of medical imaging devices for the operating room, will take place in Trinity
Room I at 11:00 a.m. on May 3, 2006 at the Toronto Marriott Eaton Centre
Hotel.

About Novadaq Technologies
Novadaq Technologies Inc. (TSX: NDQ) develops and commercializes medical
devices based on its proprietary imaging platform for the diagnosis and
treatment of human vascular, ophthalmic, and neurologic diseases and
conditions. Novadaq's SPY Intra-operative Imaging System, commercially
available worldwide, enables cardiac surgeons to visually assess coronary
vasculature and bypass graft functionality during the course of open-heart
bypass surgery. Novadaq's ophthalmic product, the OPTTX System, is aimed at
the diagnosis, evaluation and treatment of wet Age-related Macular
Degeneration (AMD) by using the same core imaging technology that is used in
the SPY System. The OPTTX System is currently being evaluated in clinical
trials. Novadaq's product for nerve visualization in prostate surgery,
LUNA(TM) is designed to enable surgeons to visualize nerve bundles during the
course of radical prostatectomy in order to reduce negative outcomes including
impotency. For more information, please visit the company's website at
www.novadaq.com.

Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Novadaq's
current beliefs as well as assumptions made by and information currently
available to Novadaq and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Novadaq in its public securities filings; actual
events may differ materially from current expectations. Novadaq disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
%SEDAR: 00022069E

Novadaq Technologies Inc. on 6ix

Story so far

Earlier from Novadaq Technologies

Later from Novadaq Technologies

All Novadaq Technologies news releases